United States: Method Of Treatment Claims Cancelled In View Of Prior Art Under Theory Of Obviousness, But Not Anticipation

Eli Lilly and Co. v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, (PTAB October 22, 2015)

In an inter partes review (IPR) proceeding, the Patent Trial and Appeal Board (Board) found all of Los Angeles Biomedical Research Institute's (LA-Bio Med) patent claims unpatentable on the basis of obviousness in view of a combination of published prior art. Eli Lilly and Co. v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Cases IPR-2014-00752, Final Written Decision dated October 22, 2015 (Paper 44).

The patent at issue, U.S. Patent No. 8,133,903, relates to methods of treatment of fibrotic conditions, such as erectile dysfunction (ED), with phosphodiesterase inhibitors. Claim 1 of the '903 patent is directed to "a method comprising: a) administering a ... (PDE 5) inhibitor according to a continuous long-term regimen to an individual with at least one of a penile tunical fibrosis and corporal tissue fibrosis; and b) arresting or regressing the ... tissue fibrosis, wherein the PDE-5 inhibitor is administered at a dosage up to 1.5 mg/kg/day for not less than 45 days." 

In 2013, LA-BioMed filed suit against Eli Lilly alleging the '903 patent claims encompass the use of Lilly's Cialis® (tadalafil) product for the once-daily treatment of ED. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center v. Eli Lilly and Co., No. 2:13-cv-08567 (C.D. Cal.)(stayed in view of IPR proceedings). Within the year, Eli Lilly submitted two IPR petitions challenging the validity of the '903 patent claims on the basis of anticipation and obviousness.

In the IPR proceeding addressing obviousness, the Board construed claim elements in dispute, including interpreting "continuous long-term regimen" as including administration of a drug over a period of time without intermission such that treatment is therapeutically effective, and not less that the claimed "up to 1.5 mg/kg/day 45 days" (although the later phrase was not defined)  (pages 6–7, 9). The Board did not adopt LA-BioMed's position that the claim should be narrowed such that "continuous" required maintaining a constant level of PDE-5 inhibitor. The Board found "an individual . . . with fibrosis" to be one having symptoms, but not necessarily diagnosed with, fibrosis (page 8). The Board declined to interpret "arresting or regressing ... the ... fibrosis" because that is the intended result of administering the medication (pages 8–0).

Significantly, the Board concluded that LA-Bio Med was not entitled to claim priority to its earliest 2002 provisional patent application because the claim limitation of "up to 1.5 mg/kg/day" was not adequately disclosed by an animal study that could not confirm the exact dosage of drug delivered by daily water intake and could not be readily translated to a human dosage upper limit (pages 9–13). Consequently, the primary obviousness reference (Montorsi 2002) qualified as prior art against the '903 patent.

In evaluating obviousness, the Board concluded that Eli Lilly "demonstrated by a preponderance of the evidence that claims 1-5 of the '903 patent are unpatentable" in view of two prior publications (Montorsi 2002 and Porst 2000) and published patent application to Whitaker 2001 (page 2). As to claim 1, the Board found that Montorsi 2002 disclosed that the pathophysiology underlying ED can be fibrosis, and disclosed treatment of ED using up to daily doses of 100 mg of a PDE-5 inhibitor (sildenafil) over a 12-week to six-month period, one hour before sexual activity. Whitaker 2001 disclosed the motivation for the use of a long-term (eight to 12 weeks), up to daily treatment (rather than on-demand) for ED of one to 10 milligrams Viagra® (sildenafil, but preferably tadalafil). Porst 2000 provided further motivation for continuous dosing by disclosing the safety and efficacy of daily administration of another PDE-5 inhibitor (IC351) at up to 100 milligrams for three weeks to treat ED (pages 13–19). The Board agreed with Eli Lilly that a skilled artesian would have "had a reasonable expectation of success of achieving the claimed invention because Montorsi teaches early intervention, Whitaker teaches daily administration, and Porst teaches that the administration of 100 milligrams per day of a PDE-5 inhibitor was safe and generally well tolerated" (page 20). The Board did not find persuasive LA-Bio Med's arguments relating to unexpected results in view of or teaching away by the prior art. The Board found claims 2-5 unpatentable for the same reasons and because no additional basis for patentability was presented (page 28). In December, LA-Bio Med filed a notice of appeal to the final decision on obviousness.

In the IPR proceeding addressing anticipation, Eli Lilly contended that the '903 patent claims 1-5 were unpatentable for being anticipated by Whitaker 2001 alone. However, the Board found that Whitaker did not disclose all of the elements of claim 1. Specifically, the Board concluded that Whitaker lacked a disclosure of daily administration of a PDE-5 inhibitor, even though the title of the Whitaker patent is "Daily treatment for the erectile dysfunction using a PDE5 inhibitor," and discloses "...administration...preferably daily as long as the patient suffers from [ED]..."  The Board found Whitaker's description of the clinical study assessing efficacy of a PDE-5 inhibitor for the treatment of ED wherein men took the study drug, "greater than 70 percent of the time during the study" (lasting eight to twelve weeks) to not inherently disclose daily dosing for at least 45 days, as claimed. Eli Lilly has filed a notice of appeal to the final decision on anticipation.

Method Of Treatment Claims Cancelled In View Of Prior Art Under Theory Of Obviousness, But Not Anticipation

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions